Navigation Links
Study Attributes Elevated Liver Enzymes in HIV/hepatitis to Coinfection Rather Than Antiretrovirals

Many HIV/hepatitis coinfected individuals on antiretroviral therapy (ART) experience liver enzyme elevation (LEE), and for that reason,// caution is generally advised when prescribing ART in this population. Results from the ICoNA (Italian Cohort of Na?ve for Antiretrovirals) study indicate that coinfection itself may be the major risk factor for LEE.

The study investigated whether coinfected individuals on antiretroviral therapy had a higher risk of LEE than coinfected patients who were not on therapy. Results indicate this may not be the case.

ICoNA is an Italian prospective observational study of HIV-infected patients enrolled when na?ve for antiretroviral therapy. Included in this analysis were patients with one or more positive HCV antibody tests and more than one positive HBV surface antigen. Patients who began ART with one or two drugs were excluded from the analysis, as were those with signs and symptoms of acute hepatitis.

LEE was defined as alanine aminotransferase (ALT) levels (>5 x the baseline level or >3.5 x baseline when the baseline was >40 IU/l). Changes of ALT from time of enrolment in the study were analysed as a continuous variable to see if findings were affected by the choice of a cut-off point to define elevation.

HBV or HCV coinfection, use of ART, baseline ALT, and demographics were analysed using Poisson regression with generalized estimating equation correction to identify the most important predictors for the development of LEE. Demographics included age, body mass index, African origin, and risk factors for HIV infection.

The analysis included 5,272 patients of whom 30% were female, 39% were intravenous drug users, and nearly 48% were HCV/HBV coinfected. In the 18,259 person years follow-up, there were 275 episodes of LEE. The use of ART did not significantly increase the risk of LEE (adjusted RR 1.19); however, coinfection did (adjusted RR 5.07) with no significant differences between those taking ART and those who were therapy na?ve. Males tended to have a higher risk of LEE than females.

The authors noted that one potential limitation of the study was that HCV-positive patients who were non-viraemic were analysed as being HCV coinfected; but, in a sample of the cohort, there was only a small proportion of patients with HCV antibodies and undetectable HCV RNA. Data on alcohol intake were also not included in the multivariate analysis.

Of clinical significance in this study were that there was no increase in the risk of LEE for patients on ART and that the risk of LEE in coinfected patients is not modified by the use of ART. Longer follow-up is needed to confirm these findings. Also of interest would be further explanation of a male gender-associated risk of LEE.



Source-Bio-Bio Technology
'"/>




Related medicine news :

1. Tomato Sauce reduces Cancer Risk- Study
2. Study on obesity and heart failure
3. National Lung Study in the process
4. Study casts doubt on keyboard ills
5. Study reveals how stress can make you sick
6. Study reveals how stress can make you sick
7. Study supports vegetable diet
8. Study to look at early surgery to treat epilepsy
9. Its Never Too Late to Stop Smoking,Study Finds
10. New Technique to Study Infants Brain.
11. Groundbreaking Study Gives Hope For Patients With Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/24/2017)... ... , ... Only two months after the official release of The Private Collection ... XO Private has initiated a second print-run of its lavish luxury travel coffee table ... when open, weighs in at more than six kilos, retails at EUR 1,000 per ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... In the ... to be a top priority because it’s not if you will be attacked, but ... especially when it comes to digital health care. , Improvements in auditing and monitoring ...
(Date:2/24/2017)... ... ... The California State University Institute for Palliative Care is pleased ... palliative care education and research. The Symposium, “Innovate. Investigate. Educate: Advancing Academic Palliative ... Sept. 28 and 29, 2017, on the campus of California State University San Marcos. ...
(Date:2/24/2017)... ... February 24, 2017 , ... Rosica Communications, a national ... , media relations, social media, content marketing and SEO, is now offering direct, ... an intuitive marketing automation platform. , Rosica will now offer the platform to ...
(Date:2/23/2017)... , ... February 23, 2017 , ... The 89th Academy ... winner of the 2016 National Education Policy Center Bunkum Award. We invite you to ... 2016. , This year’s Bunkum winner is the Center for American Progress (CAP), for ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 24, 2017 Juan ... & Associates PC , a boutique securities firm headquartered ... York City , announces that a class action ... Massachusetts  against Inotek Pharmaceuticals Corporation (NASDAQ: ... the Company,s securities between July 23, 2015 and December 30, ...
(Date:2/24/2017)... , Feb. 23, 2017  Directors from Pharma To Market Pty ... have joined forces, resulting in the founding of Pharma To Market ... Pharma To Market are pleased to announce their expansion into ... Singapore . The company are delighted to appoint ... of the Singapore based entity. Joelle brings ...
(Date:2/24/2017)... , Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., ... announced that it has acquired exclusive worldwide rights ... best-in-class innovative HDAC inhibitor targeting hematological and solid ... 14 Phase 1 and 2 clinical trials of ... have already been completed, demonstrating that ...
Breaking Medicine Technology: